Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report

Crizotinib is one of the molecularly-targeted agents targeted against anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). Although its effects appear to be promising, crizotinib may cause adverse effects in patients with ALK-rearranged NSCLC. Hepatic laboratory abnormalit...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and clinical oncology 2017-08, Vol.7 (2), p.295-297
Main Authors: Yasuda, Yuto, Nishikawa, Yasuyo, Sakamori, Yuichi, Terao, Makoto, Hashimoto, Kentaro, Funazo, Tomoko, Nomizo, Takashi, Tsuji, Takahiro, Yoshida, Hironori, Nagai, Hiroki, Ozasa, Hiroaki, Hirai, Toyohiro, Kim, Young Hak
Format: Article
Language:English
Subjects:
Crizotinib
Development and progression
Drug therapy
Non-small cell lung cancer
Patient outcomes
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Crizotinib is one of the molecularly-targeted agents targeted against anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). Although its effects appear to be promising, crizotinib may cause adverse effects in patients with ALK-rearranged NSCLC. Hepatic laboratory abnormalities are frequently observed with crizotinib and treatment discontinuation is occasionally required. We herein report the case of a 51-year-old woman diagnosed with relapsed ALK-rearranged NSCLC, who received crizotinib as second-line systemic chemotherapy. After 17 days of crizotinib therapy, the patient developed grade >3 hepatotoxicity. Treatment discontinuation improved the laboratory abnormalities and fifth-line oral desensitization with crizotinib achieved successful response without hepatotoxicity. Therefore, oral desensitization with crizotinib may be a viable option following crizotinib-induced hepatitis.
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2017.1310